Home LiteratureArticle Details
PMID: 19148281 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes.

PLoS pathogens ·Vol. 5 ·No. 1 ·2009-01-00 ·Pages e1000269

Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG

Abstract

The mechanisms of liver injury associated with chronic HCV infection, as well as the individual roles of both viral and host factors, are not clearly defined. However, it is becoming increasingly clear that direct cytopathic effects, in addition to immune-mediated processes, play an important role in liver injury. Gene expression profiling during multiple time-points of acute HCV infection of cultured Huh-7.5 cells was performed to gain insight into the cellular mechanism of HCV-associated cytopathic effect. Maximal induction of cell-death-related genes and appearance of activated caspase-3 in HCV-infected cells coincided with peak viral replication, suggesting a link between viral load and apoptosis. Gene ontology analysis revealed that many of the cell-death genes function to induce apoptosis in response to cell cycle arrest. Labeling of dividing cells in culture followed by flow cytometry also demonstrated the presence of significantly fewer cells in S-phase in HCV-infected relative to mock cultures, suggesting HCV infection is associated with delayed cell cycle progression. Regulation of numerous genes involved in anti-oxidative stress response and TGF-beta1 signaling suggest these as possible causes of delayed cell cycle progression. Significantly, a subset of cell-death genes regulated during in vitro HCV infection was similarly regulated specifically in liver tissue from a cohort of HCV-infected liver transplant patients with rapidly progressive fibrosis. Collectively, these data suggest that HCV mediates direct cytopathic effects through deregulation of the cell cycle and that this process may contribute to liver disease progression. This in vitro system could be utilized to further define the cellular mechanism of this perturbation.

MeSH Terms
Apoptosis/genetics,physiology Cell Cycle/physiology Cell Line, Tumor Cells, Cultured Cytokines/physiology Hepacivirus/genetics,physiology Hepatitis C/physiopathology Hepatocytes/cytology,virology Humans Liver Transplantation/pathology,physiology
Chemicals
Cytokines
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Walters Kathie-Anne
Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, United States of America.
Syder Andrew J
Lederer Sharon L
Diamond Deborah L
Paeper Bryan
Rice Charles M
Katze Michael G
References (51)
51 references, click to expand
  1. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.
    Gastroenterology. 2007 Nov;133(5):1649-59 PMID: 17983809
  2. Cell-cycle dysregulation in the immunopathogenesis of AIDS.
    Immunol Res. 2004;29(1-3):253-68 PMID: 15181287
  3. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.
    Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3805-9 PMID: 16484368
  4. HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1.
    Virology. 2003 Sep 15;314(1):271-82 PMID: 14517080
  5. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate.
    Hepatology. 2000 Aug;32(2):418-26 PMID: 10915752
  6. p53 in signaling checkpoint arrest or apoptosis.
    Curr Opin Genet Dev. 1996 Feb;6(1):12-8 PMID: 8791489
  7. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway.
    J Virol. 2008 Nov;82(21):10375-85 PMID: 18768989
  8. Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation.
    J Clin Microbiol. 1996 Nov;34(11):2702-6 PMID: 8897168
  9. Convergence of p53 and TGF-beta signaling networks.
    Cancer Lett. 2004 Sep 30;213(2):129-38 PMID: 15327827
  10. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection.
    Gastroenterology. 2005 Jan;128(1):33-42 PMID: 15633121
  11. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr.
    Exp Cell Res. 1999 Aug 25;251(1):156-65 PMID: 10438581
  12. Hepatocyte expression of minichromosome maintenance protein-2 predicts fibrosis progression after transplantation for chronic hepatitis C virus: a pilot study.
    Liver Transpl. 2005 Apr;11(4):427-33 PMID: 15776414
  13. HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression.
    Virus Res. 2006 Nov;121(2):134-43 PMID: 16797769
  14. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation.
    Hepatology. 1997 Nov;26(5):1343-50 PMID: 9362382
  15. TGF-beta-dependent cell growth arrest and apoptosis.
    J Biochem Mol Biol. 2002 Jan 31;35(1):47-53 PMID: 16248969
  16. Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes.
    Virology. 2006 Mar 15;346(2):348-62 PMID: 16325882
  17. Transforming growth factor-beta 1 in chronic hepatitis C.
    J Viral Hepat. 1997 Jan;4(1):29-35 PMID: 9031062
  18. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.
    PLoS Pathog. 2006 Jun;2(6):e59 PMID: 16789836
  19. Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression.
    J Biol Chem. 2004 Mar 19;279(12):11719-26 PMID: 14711830
  20. Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events.
    J Virol. 2001 May;75(9):4321-31 PMID: 11287581
  21. Mechanisms of Disease: HCV-induced liver injury.
    Nat Clin Pract Gastroenterol Hepatol. 2007 Nov;4(11):622-34 PMID: 17978819
  22. Perturbations of cell cycle control in T cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys.
    J Virol. 2006 Jan;80(2):634-42 PMID: 16378966
  23. Dysregulation of the polo-like kinase pathway in CD4+ T cells is characteristic of pathogenic simian immunodeficiency virus infection.
    J Virol. 2004 Feb;78(3):1464-72 PMID: 14722302
  24. Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression.
    J Virol. 2006 Feb;80(3):1181-90 PMID: 16414995
  25. Genomic analysis of the host response to hepatitis B virus infection.
    Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6669-74 PMID: 15100412
  26. Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.
    Am J Pathol. 2007 Dec;171(6):1831-46 PMID: 17991716
  27. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
    Oncogene. 2000 Jul 13;19(30):3384-94 PMID: 10918595
  28. Complete replication of hepatitis C virus in cell culture.
    Science. 2005 Jul 22;309(5734):623-6 PMID: 15947137
  29. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation.
    J Virol. 2006 Jul;80(14):7199-207 PMID: 16809325
  30. Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle.
    Virology. 2003 Jul 20;312(1):245-53 PMID: 12890637
  31. Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity.
    Virology. 2008 Feb 5;371(1):71-85 PMID: 17949770
  32. Chronic hepatitis. An update on terminology and reporting.
    Am J Surg Pathol. 1995 Dec;19(12):1409-17 PMID: 7503362
  33. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients.
    Gastroenterology. 2006 Jan;130(1):179-87 PMID: 16401481
  34. Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation.
    J Mol Biol. 2006 May 26;359(1):22-34 PMID: 16616934
  35. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells.
    J Virol. 2006 Oct;80(20):10253-7 PMID: 17005703
  36. The immunopathogenesis of hepatitis C virus infection.
    Clin Liver Dis. 2001 Nov;5(4):931-53 PMID: 11685802
  37. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.
    Hepatol Res. 2007 Aug;37(8):579-95 PMID: 17517074
  38. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
    Nat Med. 2005 Jul;11(7):791-6 PMID: 15951748
  39. Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells.
    Cancer Biol Ther. 2003 Jul-Aug;2(4):406-15 PMID: 14508115
  40. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.
    Nat Genet. 2001 Dec;29(4):365-71 PMID: 11726920
  41. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.
    Hepatology. 2006 Dec;44(6):1607-16 PMID: 17133491
  42. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression.
    J Biol Chem. 2006 Sep 1;281(35):25134-42 PMID: 16798743
  43. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels.
    Liver Transpl Surg. 1998 Jan;4(1):15-21 PMID: 9457962
  44. Mechanisms of TGF-beta-mediated apoptosis.
    Cell Tissue Res. 2002 Jan;307(1):1-14 PMID: 11810309
  45. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis.
    Clin Chim Acta. 2002 Feb;316(1-2):83-94 PMID: 11750277
  46. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production.
    J Biol Chem. 2005 Nov 11;280(45):37481-8 PMID: 16150732
  47. Robust hepatitis C virus infection in vitro.
    Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9 PMID: 15939869
  48. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein.
    Gastroenterology. 2002 Feb;122(2):366-75 PMID: 11832451
  49. Altered expression of cell cycle and apoptotic proteins in chronic hepatitis C virus infection.
    BMC Microbiol. 2008 Aug 05;8:133 PMID: 18680610
  50. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology.
    J Gastroenterol Hepatol. 2003 Nov;18(11):1302-8 PMID: 14535988
  51. Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo.
    J Virol. 2006 Mar;80(5):2280-90 PMID: 16474135
Article Info
Journal
PLoS pathogens
Abbr.
PLoS Pathog
ISSN
1553-7374
Published
2009-01-00
Epub
2009-00-16
Pages
e1000269
Language
English
Region
United States
NLM ID
101238921
PMCID
PMC2613535
Subset
IM
Grants
NIDA NIH HHS · R37 DA004334 · United States
NIAID NIH HHS · U19AI040034 · United States
NIDA NIH HHS · 1R37DA004334 · United States
NHLBI NIH HHS · R01 HL080621 · United States
NIAID NIH HHS · 5U19AI48214 · United States
NIDA NIH HHS · P30 DA015625 · United States
NIDA NIH HHS · R01 DA016078 · United States
NIDA NIH HHS · 1P30DA01562501 · United States
NIDA NIH HHS · 5P30DA015625-07 · United States
PHS HHS · 5R01A1049168 · United States
NIDA NIH HHS · R01 DA012568 · United States
NCI NIH HHS · 5R01CA074131 · United States
NIAID NIH HHS · 5P01AI058113-050006 · United States
NIAID NIH HHS · 5R21AI071892-02 · United States
NCI NIH HHS · R01 CA074131 · United States
NCI NIH HHS · R01CA57973 · United States
NIDA NIH HHS · R01DA12568 · United States
NIAID NIH HHS · R21 AI071892 · United States
NHLBI NIH HHS · 5R01HL080621-03 · United States
NIAID NIH HHS · U19 AI040034 · United States
NIDA NIH HHS · R01DA16078 · United States
NIDDK NIH HHS · DK70497 · United States
NIAID NIH HHS · U19 AI048214 · United States
NCI NIH HHS · R01 CA057973 · United States
NIDDK NIH HHS · F32 DK070497 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com